Skip to main content
Solid radium sulfate sits in the bottom of a flask during the recovery process. Credit: Oak Ridge National Laboratory, U.S. Dept. of Energy

Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.

Nuclear — Seeing inside particles

Oak Ridge National Laboratory researchers working on neutron imaging capabilities for nuclear materials have developed a process for seeing the inside of uranium particles – without cutting them open.

exp_in_10_dry_tube.jpg

Scientists from Oak Ridge National Laboratory performed a corrosion test in a neutron radiation field to support the continued development of molten salt reactors.

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.

COHERENT collaborators were the first to observe coherent elastic neutrino–nucleus scattering. Their results, published in the journal Science, confirm a prediction of the Standard Model and establish constraints on alternative theoretical models. Image c

After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.